T-Zelltherapien in der Onkologie

Literatur

• 1 Andersen M H, Pedersen L O, Capeller B, Brocker E B, Becker J C, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.  Cancer Res. 2001;  61 5964-5968
• 2 Anderson K C, Weinstein H J. Transfusion-associated graft-versus-host disease.  N Engl J Med. 1990;  323 315-321
• 3 Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.  Blood. 2001;  97 2903-2907
• 4 Barnes D WH, Corp M J, Loutit J F, Neal F E. Treatment of murine leukemea with x-rays and homologous bone marrow. Preliminary communication.  Br Med J. 1956;  2 626-627
• 5 Biggs J C, Szer J, Crilley P. et al . Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2.  Blood. 1992;  80 1352-1357
• 6 Bocchia M, Bronte V, Colombo M P. et al . Antitumor vaccination: where we stand.  Haematologica. 2000;  85 1172-1206
• 7 Champlin R, Khouri I, Anderlini P. et al . Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.  Bone Marrow Transplant. 2001;  27 (Suppl 2) S13-22
• 8 Childs R, Chernoff A, Contentin N. et al . Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.  N Engl J Med. 2000;  343 750-758
• 9 Clark R E, Dodi I A, Hill S C. et al . Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.  Blood. 2001;  98 2887-2893
• 10 Clay T M, Custer M C, Sachs J, Hwu P, Rosenberg S A, Nishimura M I. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity.  J Immunol. 1999;  163 507-513
• 11 Coulie P G, Ikeda H, Baurain J F, Chiari R. Antitumor immunity at work in a melanoma patient.  Adv Cancer Res. 1999;  76 213-242
• 12 Coulie P G, Karanikas V, Colau D. et al . A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.  Proc Natl Acad Sci U S A. 2001;  98 10 290-10 295
• 13 Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy D C, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease.  Nat Med. 2001;  7 789-794
• 14 Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi P P, Pelicci P G, Parmiani G. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.  Blood. 1993;  81 1369-1375
• 15 Gao L, Bellantuono I, Elsasser A. et al . Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1.  Blood. 2000;  95 2198-2203
• 16 Gillis S, Smith K. Long term culture of tumor-specific cytotoxic T cells.  Nature. 1977;  268 154-156
• 17 Goulmy E, Termijtelen A, Bradley B A, van Rood J J. Y antigen killing by women is restricted by HLA.  Nature. 1977;  266 544-545
• 18 Hausmann J, Hallensleben W, de la Torre J C. et al . T cell ignorance in mice to Borna disease virus can be overcome by peripheral expression of the viral nucleoprotein.  Proc Natl Acad Sci U S A. 1999;  96 9769-9774
• 19 Herr W, Linn B, Leister N, Wandel E, Meyer zum Büschenfelde K-H, Wölfel T. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens.  J Immunol Methods. 1997;  203 141-152
• 20 Holler P D, Holman P O, Shusta E V, O’Herrin S, Wittrup K D, Kranz D M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC.  Proc Natl Acad Sci U S A. 2000;  97 5387-5392
• 21 Jäger E, Ringhoffer M, Altmannsberger M. et al . Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.  Int J Cancer. 1997;  71 142-147
• 22 Kessels H W, Wolkers M C, van den Boom M D, van der Valk M A, Schumacher T N. Immunotherapy through TCR gene transfer.  Nat Immunol. 2001;  2 957-961
• 23 Koh M B, Prentice H G, Lowdell M W. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.  Bone Marrow Transplant. 1999;  23 1071-1079
• 24 Kolb H J, Mittermüller J, Clemm C. et al . Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.  Blood. 1990;  76 2462-2465
• 25 Kugler A, Stuhler G, Walden P. et al . Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.  Nat Med. 2000;  6 332-336
• 26 Marchand M, van Baren N, Weynants P. et al . Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.  Int J Cancer. 1999;  80 219-230
• 27 McMichael A J, Gotch F M, Noble G R, Beare P AS. Cytotoxic T cell immunity to influenza.  N Engl J Med. 1983;  309 13-17
• 28 McSweeney P A, Niederwieser D, Shizuru J A. et al . Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.  Blood. 2001;  97 3390-3400
• 29 Mocellin S, Ohnmacht G A, Wang E, Marincola F M. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness.  Int J Cancer. 2001;  93 236-242
• 30 Molldrem J J, Lee P P, Wang C. et al . Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia.  Nat Med. 2000;  6 1018-1023
• 31 Mutis T, Gillespie G, Schrama E, Falkenburg J H, Moss P, Goulmy E. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.  Nat Med. 1999;  5 839-842
• 32 Nestle F O, Alijagic S, Gilliet M. et al . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.  Nat Med. 1998;  4 328-332
• 33 Ochsenbein A F, Klenerman P, Karrer U. et al . Immune surveillance against a solid tumor fails because of immunological ignorance.  Proc Natl Acad Sci U S A. 1999;  96 2233-2238
• 34 Rammensee H -G, Falk K, Rötzschke O. MHC molecules as peptide receptors.  Curr Opin Immunol. 1993;  5 35-44
• 35 Read S, Powrie F. CD4(+) regulatory T cells.  Curr Opin Immunol. 2001;  13 644-649
• 36 Riddell S R, Watanabe K S, Goodrich J M, Li C R, Agha M E, Greenberg P D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.  Science. 1992;  257 238-241
• 37 Romero P, Cerottini J C, Waanders G A. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy.  Mol Med Today. 1998;  4 305-312
• 38 Rooney C M, Smith C A, Ng C Y. et al . Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.  Blood. 1998;  92 1549-1555
• 39 Roy-Proulx G, Meunier M C, Lanteigne A M, Brochu S, Perreault C. Immunodomination results from functional differences between competing CTL.  Eur J Immunol. 2001;  31 2284-2292
• 40 Ruggeri L, Capanni M, Martelli M F, Velardi A. Cellular therapy: exploiting NK cell alloreactivity in transplantation.  Curr Opin Hematol. 2001;  8 355-359
• 41 Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.  Nature. 1999;  401 708-712
• 42 Sette A, Chesnut R, Fikes J. HLA expression in cancer: implications for T cell-based immunotherapy.  Immunogenetics. 2001;  53 255-263
• 43 Smyth M J, Godfrey D I, Trapani J A. A fresh look at tumor immunosurveillance and immunotherapy.  Nat Immunol. 2001;  2 293-299
• 44 Stanislawski T, Voss R H, Lotz C. et al . Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.  Nat Immunol. 2001;  2 962-970
• 45 Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings.  N Engl J Med. 1992;  327 1613-1617
• 46 Thurner B, Haendle I, Roder C. et al . Vaccination with MAGE-3/A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.  J Exp Med. 1999;  190 1669-1678
• 47 Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes.  Ann Rev Immunol. 1989;  7 601-624
• 48 Vermorken J B, Claessen A M, van Tinteren H. et al . Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.  Lancet. 1999;  353 345-350
• 49 Vierboom M P, Nijman H W, Offringa R. et al . Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.  J Exp Med. 1997;  186 695-704
• 50 von Boehmer H. Thymic selection: a matter of life and death.  Immunol Today. 1992;  13 454-458
• 51 Wölfel T, Hauer M, Schneider J. et al . A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.  Science. 1995;  269 1281-1284
• 52 Yee C, Thompson J A, Roche P. et al . Melanocyte destruction after antigen-specific immunotherapy of melanoma. Direct evidence of T cell-mediated vitiligo.  J Exp Med. 2000;  192 1637-1644
• 53 Yotnda P, Garcia F, Peuchmaur M. et al . Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia.  J Clin Invest. 1998;  102 455-462
• 54 Yun C, Senju S, Fujita H. et al . Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein.  Tissue Antigens. 1999;  54 153-161